GERON CORP Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period
GERON CORP (GERN) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period of 625 shares for the 12-month period ending 2015-12-31, per its 10-K filed 2016-03-10.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod · last filed 2016-03-10
- GERON CORP share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2015 was 625.00 shares, a 99.56% decline from fiscal 2014.
- GERON CORP share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2014 was 142.38K shares, a 94.17% decline from fiscal 2013.
- GERON CORP share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2013 was 2.44M shares, a 6.83% decline from fiscal 2012.
- GERON CORP share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2012 was 2.62M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 12 month |
|---|---|
| 2015-12-31 | 625.00 shares 10-K · filed 2016-03-10 |
| 2014-12-31 | 142.38K shares 10-K · filed 2015-03-11 |
| 2013-12-31 | 2.44M shares 10-K · filed 2014-03-17 |
| 2012-12-31 | 2.62M shares 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |